- Home
- LUNG vs RDIB Comparison
LUNG vs RDIB Comparison
Compare LUNG & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- RDIB
- Stock Information
- Founded
- LUNG 1995
- RDIB 1937
- Country
- LUNG United States
- RDIB United States
- Employees
- LUNG N/A
- RDIB N/A
- Industry
- LUNG Industrial Specialties
- RDIB Movies/Entertainment
- Sector
- LUNG Health Care
- RDIB Consumer Discretionary
- Exchange
- LUNG Nasdaq
- RDIB Nasdaq
- Market Cap
- LUNG 124.0M
- RDIB 140.2M
- IPO Year
- LUNG 2020
- RDIB N/A
- Fundamental
- Price
- LUNG $2.67
- RDIB $9.51
- Analyst Decision
- LUNG Buy
- RDIB
- Analyst Count
- LUNG 6
- RDIB 0
- Target Price
- LUNG $11.53
- RDIB N/A
- AVG Volume (30 Days)
- LUNG 366.5K
- RDIB 6.7K
- Earning Date
- LUNG 07-30-2025
- RDIB 08-13-2025
- Dividend Yield
- LUNG N/A
- RDIB N/A
- EPS Growth
- LUNG N/A
- RDIB N/A
- EPS
- LUNG N/A
- RDIB N/A
- Revenue
- LUNG $87,473,000.00
- RDIB $205,644,000.00
- Revenue This Year
- LUNG $18.02
- RDIB $7.47
- Revenue Next Year
- LUNG $18.17
- RDIB $13.22
- P/E Ratio
- LUNG N/A
- RDIB N/A
- Revenue Growth
- LUNG 19.84
- RDIB N/A
- 52 Week Low
- LUNG $2.62
- RDIB $5.78
- 52 Week High
- LUNG $9.37
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- LUNG 33.53
- RDIB 45.18
- Support Level
- LUNG $2.62
- RDIB $9.00
- Resistance Level
- LUNG $3.52
- RDIB $12.72
- Average True Range (ATR)
- LUNG 0.23
- RDIB 1.33
- MACD
- LUNG 0.02
- RDIB -0.12
- Stochastic Oscillator
- LUNG 13.46
- RDIB 19.13
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.